Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Immunogen Inc (NQ: IMGN )

4.265 -0.045 (-1.04%)
Streaming Delayed Price Updated: 9:40 AM EDT, Jun 27, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Immunogen Inc

< Previous 1 2 3 Next >
Immunogen's Return On Capital Employed Overview
According to Benzinga Pro data, during Q1, Immunogen (NASDAQ:IMGN) posted sales of $38.08 million. Earnings were up 35.05%, but Immunogen still reported an overall loss of $24.14 million. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
What's Going On With ImmunoGen Shares Today?
ImmunoGen, Inc. (NASDAQ: IMGN) shares are trading flat at $3.57 after the company's Biologics License Application to treat ovarian cancer was accepted by the FDA with priority review. 
Via Benzinga
Immunogen: Q1 Earnings Insights
Immunogen (NASDAQ:IMGN) reported its Q1 earnings results on Friday, May 6, 2022 at 07:30 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Immunogen Earnings Preview
Immunogen (NASDAQ:IMGN) is set to give its latest quarterly earnings report on Friday, 2022-05-06. Here's what investors need to know before the announcement. Analysts estimate that Immunogen will... 
Via Benzinga
The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More
Biotech stocks posted weekly declines yet again in the week ending April 29, taking cues from the weak broader market sentiment. Big pharma earnings, clinical readouts and pipeline updates moved stocks... 
Via Benzinga
Earnings Scheduled For May 6, 2022
Companies Reporting Before The Bell • Brookfield Renewable (NYSE:BEP) is expected to report quarterly loss at $0.02 per share on revenue of $1.27 billion. 
Via Benzinga
Why Are ImmunoGen Shares Trading Lower Today
ImmunoGen Inc (NASDAQ: IMGN)  
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers 
Via Benzinga
The Daily Biotech Pulse: Sanofi-IGM Ink Antibody Drug Collaboration; NeoGenomics Sinks On CEO Departure, Q1 Warning; Decision Day For Akebia
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers 
Via Benzinga
75 Biggest Movers From Yesterday
Gainers NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) shares jumped 299.4% to close at $6.23 on Monday as the company received clearance from the FDA to initiate a pharmacokinetic... 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
During Monday's session, 39 stocks hit new 52-week lows. Interesting Facts About Today's 52-Week Lows: The largest company in terms of market cap to set a... 
Via Benzinga
46 Stocks Moving In Monday's Mid-Day Session
Gainers NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) climbed 369% to $7.32 as the company received clearance from the FDA to initiate a pharmacokinetic study of PrimeC in... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 21, 2022
Upgrades According to B. Riley Securities, the prior rating for BRT Apartments Corp (NYSE:BRT) was changed from Neutral to Buy. BRT Apartments earned $0.41 in the fourth quarter,... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Corbus Pharmaceuticals (NASDAQ:CRBP) shares increased by 20.3% to $0.4 during Monday's pre-market session. The market value of their outstanding shares is at $49.7 million. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Welcome back, investor! We're getting right into the thick of it with a look at the biggest pre-market stock movers for Monday! 
Via InvestorPlace
28 Stocks Moving in Monday's Pre-Market Session
Gainers BitNile Holdings, Inc. (NYSE: NILE) rose 61.1% to $0.90 in pre-market trading. BitNile's TurnOnGreen resumed expansion of its electric vehicle charging network and e-... 
Via Benzinga
The Daily Biotech Pulse: Lilly's Jardiance Gets Nod For Heart Failure, Pulmatrix Announces Reverse Split, Reata Awaits FDA Decision
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Lilly's Co-developed Diabetes Drug Jardiance Gets Label Expansion To... 
Via Benzinga
Immunogen: Q4 Earnings Insights
Immunogen (NASDAQ:IMGN) reported its Q4 earnings results on Friday, February 25, 2022 at 06:30 AM. Here's what investors need to know about the announcement. Earnings... 
Via Benzinga
Earnings Outlook For Immunogen
Immunogen (NASDAQ:IMGN) is set to give its latest quarterly earnings report on Friday, 2022-02-25. Here's what investors need to know before the announcement. Analysts estimate... 
Via Benzinga
Lilly Unites With ImmunoGen In ADC Deal Worth Up To $1.7B
ImmunoGen Inc (NASDAQ: IMGN) has struck a multi-target license deal with Eli Lilly And Co (NYSE: LLY) to grant exclusive rights to research, develop, and... 
Via Benzinga
Sutro Biopharma Collapses; Why One Analyst Remains Bullish On Its Chances In Cancer
Sutro Biopharma could still find a place for itself in ovarian cancer treatment. 
Via Investor's Business Daily
Earnings Scheduled For February 25, 2022
Companies Reporting Before The Bell • ACM Research (NASDAQ:ACMR) is estimated to report quarterly earnings at $0.64 per share on revenue of $89.53 million. •... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 1, 2021
Upgrades Goldman Sachs upgraded the previous rating for Grupo Aeroportuario del Sureste SAB de CV 
Via Benzinga
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front... 
Via Benzinga
The Daily Biotech Pulse: Adcom Backs Merck's Oral COVID-19 Treatment; Regulatory Setbacks For CTI Biopharma, BioXcel; Favorable Ruling For Viatris In Tecfidera Patent Case
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Adcom Backing For Oral COVID-19 Antiviral Medication Molnupiravir... 
Via Benzinga
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More
The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative... 
Via Benzinga
Exposures Product Safety
61 Biggest Movers From Yesterday
Gainers Arbutus Biopharma Corporation (NASDAQ: ABUS) shares jumped 44.1% to close $4.61 on above-average volume on Wednesday. The Patent Trial and Appeals Board has turned down... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
50 Stocks Moving In Wednesday's Mid-Day Session
Gainers Arbutus Biopharma Corporation (NASDAQ: ABUS) climbed 91.7% to $6.14 on above-average volume on Wednesday. The Patent Trial and Appeals Board has turned down Moderna's... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.